|Other Accession||NM_016302, NP_057386|
|Reactivity||Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig|
|Predicted||Human, Mouse, Rat, Rabbit, Pig, Chicken, Horse, Bovine, Dog|
|Alias Symbol||DKFZp781K0715, MGC27358, MRT2A, MRT2|
|Other Names||Protein cereblon, CRBN|
|Format||Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.|
|Reconstitution & Storage||Add 50 ul of distilled water. Final anti-CRBN antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.|
|Precautions||CRBN antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Substrate recognition component of a DCX (DDB1-CUL4-X- box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly and neuronal surface expression of large-conductance calcium-activated potassium channels in brain regions involved in memory and learning via its interaction with KCNT1. Binding of pomalidomide and other thalidomide-related drugs changes the substrate specificity of the human protein, leading to decreased degradation of MEIS2 and other target proteins and increased degradation of MYC, IRF4, IKZF1 and IKZF3.|
|Cellular Location||Cytoplasm. Nucleus. Membrane; Peripheral membrane protein|
|Tissue Location||Widely expressed. Highly expressed in brain.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Muzny D.M.,et al.Nature 440:1194-1198(2006).
Hu R.-M.,et al.Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000).
Bechtel S.,et al.BMC Genomics 8:399-399(2007).
Higgins J.J.,et al.Neurology 63:1927-1931(2004).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.